Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. (Q38008700)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

Giuseppe Biondi-Zoccai

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Antonio Abbate

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Benjamin W Van Tassell

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

217-233

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf03261881

31 January 2020

exact match

0 references

cites work

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Long-term trends in the incidence of heart failure after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Challenges and opportunities for cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Chemokines--chemotactic cytokines that mediate inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Inflammasomes: too big to miss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Is there a vulnerable plaque?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Sudden coronary death, fatal acute myocardial infarction and widespread coronary and myocardial inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Type 2 diabetes as an inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases: a multiethnic case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Meta-analysis of corticosteroid treatment in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Use of biologics in rheumatoid arthritis: current and emerging paradigms of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Targeted anticytokine therapy and the failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Blocking interleukin-1β in acute and chronic autoinflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Canakinumab: in patients with cryopyrin-associated periodic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Rilonacept--CAPS and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Recurrent angina after coronary revascularization: a clinical challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: results of the CAMI-GUIDE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Widespread Myocardial Inflammation and Infarct-Related Artery Patency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Increasing Levels of Interleukin (IL)-1Ra and IL-6 During the First 2 Days of Hospitalization in Unstable Angina Are Associated With Increased Risk of In-Hospital Coronary Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Elevated Levels of Interleukin-6 in Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

Enhanced Response of Blood Monocytes to In Vitro Lipopolysaccharide-Challenge in Patients With Recurrent Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261881

21 January 2018

Identifiers

DOI

10.1007/BF03261881

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571369%20AND%20SRC:MED&resulttype=core&format=json

release_r74vudf2yndz7muzgwjp6gb45a

31 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/r74vudf2yndz7muzgwjp6gb45a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference